Health & Fitness
Health and Fitness
Health and Fitness
Mon, February 23, 2009
Sun, February 22, 2009
Fri, February 20, 2009 EPIX Pharmaceuticals to Present Preclinical Data for Two Programs at Keystone Symposia
LEXINGTON, Mass.--([ BUSINESS WIRE ])--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform today announced poster presentations of preclinical data on EPX-102216 and EPX-105287, during the Keystone Symposia Neurobiology of Pain and Analgesia in Santa Fe, New Mexico.
On February 23, 2009, Christine Kitsos, Ph.D., principal scientist, discovery biology at EPIX is scheduled to give a poster presentation entitled, "Attenuation of Inflammatory Pain by EPX-102216, a Novel CCR2 Antagonist." CCR2 antagonists represent a novel mechanism of action for reducing the inflammatory response in several diseases by preventing macrophages (a type of inflammatory immune cell) from accumulating in body tissues. EPX-102216, wholly owned by EPIX, is a highly selective, oral CCR2 antagonist with an excellent safety profile that is being further developed for the treatment of pain. Dr. Kitsos will be presenting results that show dose-dependent efficacy in rodent models of chronic inflammatory and neuropathic pain.
On February 24, 2009, Dilara McCauley, Ph.D., director, discovery product leader at EPIX is scheduled to give a poster presentation entitled, "EPX-105287, a Highly Selective Metabotropic Glutamate 5 Receptor (mGluR5) Negative Allosteric Modulator, Reduces Writhing in Mice and Thermal Hyperalgesia in Rats." EPX-105287, also wholly owned by EPIX, is a novel, potent, highly selective mGluR5 negative allosteric modulator that is being developed for the treatment of neuropathic (chronic) pain and L-Dopa induced dyskinesia (involuntary movement). Dr. McCauley will be presenting results of EPX-105287 displaying dose-dependent efficacy in acute visceral and chronic inflammatory rodent pain models.
EPX-102216 and EPX-105287 are both internally discovered and part of EPIX's ongoing preclinical and discovery programs targeting G-Protein Coupled Receptors (GPCRs) and ion channels for the treatment of inflammatory diseases, pain and cystic fibrosis. Both molecules are wholly owned by EPIX Pharmaceuticals.
About EPIX
EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen and Cystic Fibrosis Foundation Therapeutics.
This news release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on current expectations of management. These statements relate to, among other things, our expectations regarding our drug development efforts and the timing and content of corporate presentations. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks that we face, see the disclosure contained in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
